Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PhXA41 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Timolol | ACTIVE_COMPARATOR | - |
| PhXA41 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PhXA41 | DRUG | One drop in the affected eye once daily for six months. |
| timolol | DRUG | One drop in the affected eye twice daily for six months. |
Inclusion Criteria: * Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension. * Open angle glaucoma appearing more than 6 months after cataract surgery is recognized as primary open angle glaucoma. (individuals requiring treatment bilatera...
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
PhXA41 is being developed for the treatment of glaucoma, ocular hypertension, and open angle glaucoma. These are eye conditions characterized by elevated intraocular pressure that can damage the optic nerve. PhXA41 is an ophthalmology small molecule studied in Phase 3 clinical trials in adult patients aged 40 years and older.
PhXA41 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer is the sponsor of the clinical development program for this ophthalmology asset.
PhXA41 is in Phase 3 clinical development. It is an investigational small molecule for glaucoma and ocular hypertension and has not been approved by the FDA. The Phase 3 studies of PhXA41 have been completed, and no trials are currently active.
PhXA41 has been evaluated in three completed Phase 3 trials: NCT00751127 in the United States, NCT00751062 in Scandinavia, and NCT00751049 in the United Kingdom. All three were randomized, double-blind, and active-controlled studies in patients with open angle glaucoma or ocular hypertension.
The PhXA41 Phase 3 program enrolled patients across three completed studies. NCT00751127 enrolled 268 patients, NCT00751062 enrolled 267 patients, and NCT00751049 enrolled 294 patients. All trials required participants to be at least 40 years of age and enrolled both men and women.
PhXA41 Phase 3 trials were conducted across multiple countries. NCT00751127 took place in the United States, NCT00751062 enrolled patients in Denmark, Finland, Norway, and Sweden, and NCT00751049 was conducted in the United Kingdom. All three studies are completed.